PortalPublikationenImpact of SARS-CoV-2 vaccination and monoclonal antibodies o...

Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post-CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey

Standard

Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post-CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey. / van Doesum, Jaap A; Salmanton-García, Jon; Marchesi, Francesco; Di Blasi, Roberta; Falces-Romero, Iker; Cabirta, Alba; Farina, Francesca; Besson, Caroline; Weinbergerová, Barbora; Van Praet, Jens; Schönlein, Martin; Lopez-Garcia, Alberto; Lamure, Sylvain; Guidetti, Anna; De Ramón-Sánchez, Cristina; Batinic, Josip; Gavriilaki, Eleni; Tragiannidis, Athanasios; Tisi, Maria Chiara; Plantefeve, Gaëtan; Petzer, Verena; Ormazabal-Velez, Irati; Marques de Almeida, Joyce; Marchetti, Monia; Maertens, Johan A; Machado, Marina; Kulasekararaj, Austin G; Hernández-Rivas, José Ángel; Gomes da Silva, Maria; Fernández, Noemí; Espigado, Ildefonso; Drgona, Lubos; Dragonetti, Giulia; Metafuni, Elisabetta; Calbacho, Maria; Blennow, Ola; Wolf, Dominik; van Anrooij, Bjorn; Nunes Rodrigues, Raquel; Nordlander, Anna; Martín-González, Juan-Alberto; Lievin, Raphaël; Jiménez, Moraima; Grafe, Stefanie K; Garcia-Sanz, Ramon; Córdoba, Raúl; Rahimli, Laman; van Meerten, Tom; Cornely, Oliver A; Pagano, Livio.

in: BLOOD ADV, Jahrgang 7, Nr. 11, 13.06.2023, S. 2645-2655.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

van Doesum, JA, Salmanton-García, J, Marchesi, F, Di Blasi, R, Falces-Romero, I, Cabirta, A, Farina, F, Besson, C, Weinbergerová, B, Van Praet, J, Schönlein, M, Lopez-Garcia, A, Lamure, S, Guidetti, A, De Ramón-Sánchez, C, Batinic, J, Gavriilaki, E, Tragiannidis, A, Tisi, MC, Plantefeve, G, Petzer, V, Ormazabal-Velez, I, Marques de Almeida, J, Marchetti, M, Maertens, JA, Machado, M, Kulasekararaj, AG, Hernández-Rivas, JÁ, Gomes da Silva, M, Fernández, N, Espigado, I, Drgona, L, Dragonetti, G, Metafuni, E, Calbacho, M, Blennow, O, Wolf, D, van Anrooij, B, Nunes Rodrigues, R, Nordlander, A, Martín-González, J-A, Lievin, R, Jiménez, M, Grafe, SK, Garcia-Sanz, R, Córdoba, R, Rahimli, L, van Meerten, T, Cornely, OA & Pagano, L 2023, 'Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post-CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey', BLOOD ADV, Jg. 7, Nr. 11, S. 2645-2655. https://doi.org/10.1182/bloodadvances.2022009578

APA

van Doesum, J. A., Salmanton-García, J., Marchesi, F., Di Blasi, R., Falces-Romero, I., Cabirta, A., Farina, F., Besson, C., Weinbergerová, B., Van Praet, J., Schönlein, M., Lopez-Garcia, A., Lamure, S., Guidetti, A., De Ramón-Sánchez, C., Batinic, J., Gavriilaki, E., Tragiannidis, A., Tisi, M. C., ... Pagano, L. (2023). Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post-CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey. BLOOD ADV, 7(11), 2645-2655. https://doi.org/10.1182/bloodadvances.2022009578

Vancouver

van Doesum JA, Salmanton-García J, Marchesi F, Di Blasi R, Falces-Romero I, Cabirta A et al. Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post-CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey. BLOOD ADV. 2023 Jun 13;7(11):2645-2655. https://doi.org/10.1182/bloodadvances.2022009578

Bibtex

@article{81e047d1b2d14ab1b7a4660b52308b3d,
title = "Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post-CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey",
abstract = "Patients with previous CD19-directed chimeric antigen receptor (CAR) T-cell therapy have a prolonged vulnerability to viral infections. Coronavirus disease 2019 (COVID-19) has a great impact and has previously been shown to cause high mortality in this population. Until now, real-world data on the impact of vaccination and treatment on patients with COVID-19 after CD19-directed CAR T-cell therapy are lacking. Therefore, this multicenter, retrospective study was conducted with data from the EPICOVIDEHA survey. Sixty-four patients were identified. The overall mortality caused by COVID-19 was 31%. Patients infected with the Omicron variant had a significantly lower risk of death due to COVID-19 compared with patients infected with previous variants (7% vs 58% [P = .012]). Twenty-six patients were vaccinated at the time of the COVID-19 diagnosis. Two vaccinations showed a marked but unsignificant reduction in the risk of COVID-19-caused mortality (33.3% vs 14.2% [P = .379]). In addition, the course of the disease appears milder with less frequent intensive care unit admissions (39% vs 14% [P = .054]) and a shorter duration of hospitalization (7 vs 27.5 days [P = .022]). Of the available treatment options, only monoclonal antibodies seemed to be effective at reducing mortality from 32% to 0% (P = .036). We conclude that survival rates of CAR T-cell recipients with COVID-19 improved over time and that the combination of prior vaccination and monoclonal antibody treatment significantly reduces their risk of death. This trial was registered at www.clinicaltrials.gov as #NCT04733729.",
author = "{van Doesum}, {Jaap A} and Jon Salmanton-Garc{\'i}a and Francesco Marchesi and {Di Blasi}, Roberta and Iker Falces-Romero and Alba Cabirta and Francesca Farina and Caroline Besson and Barbora Weinbergerov{\'a} and {Van Praet}, Jens and Martin Sch{\"o}nlein and Alberto Lopez-Garcia and Sylvain Lamure and Anna Guidetti and {De Ram{\'o}n-S{\'a}nchez}, Cristina and Josip Batinic and Eleni Gavriilaki and Athanasios Tragiannidis and Tisi, {Maria Chiara} and Ga{\"e}tan Plantefeve and Verena Petzer and Irati Ormazabal-Velez and {Marques de Almeida}, Joyce and Monia Marchetti and Maertens, {Johan A} and Marina Machado and Kulasekararaj, {Austin G} and Hern{\'a}ndez-Rivas, {Jos{\'e} {\'A}ngel} and {Gomes da Silva}, Maria and Noem{\'i} Fern{\'a}ndez and Ildefonso Espigado and Lubos Drgona and Giulia Dragonetti and Elisabetta Metafuni and Maria Calbacho and Ola Blennow and Dominik Wolf and {van Anrooij}, Bjorn and {Nunes Rodrigues}, Raquel and Anna Nordlander and Juan-Alberto Mart{\'i}n-Gonz{\'a}lez and Rapha{\"e}l Lievin and Moraima Jim{\'e}nez and Grafe, {Stefanie K} and Ramon Garcia-Sanz and Ra{\'u}l C{\'o}rdoba and Laman Rahimli and {van Meerten}, Tom and Cornely, {Oliver A} and Livio Pagano",
note = "Copyright {\textcopyright} 2023 American Society of Hematology.",
year = "2023",
month = jun,
day = "13",
doi = "10.1182/bloodadvances.2022009578",
language = "English",
volume = "7",
pages = "2645--2655",
journal = "BLOOD ADV",
issn = "2473-9529",
publisher = "Elsevier BV",
number = "11",

}

RIS

TY - JOUR

T1 - Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post-CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey

AU - van Doesum, Jaap A

AU - Salmanton-García, Jon

AU - Marchesi, Francesco

AU - Di Blasi, Roberta

AU - Falces-Romero, Iker

AU - Cabirta, Alba

AU - Farina, Francesca

AU - Besson, Caroline

AU - Weinbergerová, Barbora

AU - Van Praet, Jens

AU - Schönlein, Martin

AU - Lopez-Garcia, Alberto

AU - Lamure, Sylvain

AU - Guidetti, Anna

AU - De Ramón-Sánchez, Cristina

AU - Batinic, Josip

AU - Gavriilaki, Eleni

AU - Tragiannidis, Athanasios

AU - Tisi, Maria Chiara

AU - Plantefeve, Gaëtan

AU - Petzer, Verena

AU - Ormazabal-Velez, Irati

AU - Marques de Almeida, Joyce

AU - Marchetti, Monia

AU - Maertens, Johan A

AU - Machado, Marina

AU - Kulasekararaj, Austin G

AU - Hernández-Rivas, José Ángel

AU - Gomes da Silva, Maria

AU - Fernández, Noemí

AU - Espigado, Ildefonso

AU - Drgona, Lubos

AU - Dragonetti, Giulia

AU - Metafuni, Elisabetta

AU - Calbacho, Maria

AU - Blennow, Ola

AU - Wolf, Dominik

AU - van Anrooij, Bjorn

AU - Nunes Rodrigues, Raquel

AU - Nordlander, Anna

AU - Martín-González, Juan-Alberto

AU - Lievin, Raphaël

AU - Jiménez, Moraima

AU - Grafe, Stefanie K

AU - Garcia-Sanz, Ramon

AU - Córdoba, Raúl

AU - Rahimli, Laman

AU - van Meerten, Tom

AU - Cornely, Oliver A

AU - Pagano, Livio

N1 - Copyright © 2023 American Society of Hematology.

PY - 2023/6/13

Y1 - 2023/6/13

N2 - Patients with previous CD19-directed chimeric antigen receptor (CAR) T-cell therapy have a prolonged vulnerability to viral infections. Coronavirus disease 2019 (COVID-19) has a great impact and has previously been shown to cause high mortality in this population. Until now, real-world data on the impact of vaccination and treatment on patients with COVID-19 after CD19-directed CAR T-cell therapy are lacking. Therefore, this multicenter, retrospective study was conducted with data from the EPICOVIDEHA survey. Sixty-four patients were identified. The overall mortality caused by COVID-19 was 31%. Patients infected with the Omicron variant had a significantly lower risk of death due to COVID-19 compared with patients infected with previous variants (7% vs 58% [P = .012]). Twenty-six patients were vaccinated at the time of the COVID-19 diagnosis. Two vaccinations showed a marked but unsignificant reduction in the risk of COVID-19-caused mortality (33.3% vs 14.2% [P = .379]). In addition, the course of the disease appears milder with less frequent intensive care unit admissions (39% vs 14% [P = .054]) and a shorter duration of hospitalization (7 vs 27.5 days [P = .022]). Of the available treatment options, only monoclonal antibodies seemed to be effective at reducing mortality from 32% to 0% (P = .036). We conclude that survival rates of CAR T-cell recipients with COVID-19 improved over time and that the combination of prior vaccination and monoclonal antibody treatment significantly reduces their risk of death. This trial was registered at www.clinicaltrials.gov as #NCT04733729.

AB - Patients with previous CD19-directed chimeric antigen receptor (CAR) T-cell therapy have a prolonged vulnerability to viral infections. Coronavirus disease 2019 (COVID-19) has a great impact and has previously been shown to cause high mortality in this population. Until now, real-world data on the impact of vaccination and treatment on patients with COVID-19 after CD19-directed CAR T-cell therapy are lacking. Therefore, this multicenter, retrospective study was conducted with data from the EPICOVIDEHA survey. Sixty-four patients were identified. The overall mortality caused by COVID-19 was 31%. Patients infected with the Omicron variant had a significantly lower risk of death due to COVID-19 compared with patients infected with previous variants (7% vs 58% [P = .012]). Twenty-six patients were vaccinated at the time of the COVID-19 diagnosis. Two vaccinations showed a marked but unsignificant reduction in the risk of COVID-19-caused mortality (33.3% vs 14.2% [P = .379]). In addition, the course of the disease appears milder with less frequent intensive care unit admissions (39% vs 14% [P = .054]) and a shorter duration of hospitalization (7 vs 27.5 days [P = .022]). Of the available treatment options, only monoclonal antibodies seemed to be effective at reducing mortality from 32% to 0% (P = .036). We conclude that survival rates of CAR T-cell recipients with COVID-19 improved over time and that the combination of prior vaccination and monoclonal antibody treatment significantly reduces their risk of death. This trial was registered at www.clinicaltrials.gov as #NCT04733729.

U2 - 10.1182/bloodadvances.2022009578

DO - 10.1182/bloodadvances.2022009578

M3 - SCORING: Journal article

C2 - 37058479

VL - 7

SP - 2645

EP - 2655

JO - BLOOD ADV

JF - BLOOD ADV

SN - 2473-9529

IS - 11

ER -